AU2011261501B2 - Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone - Google Patents

Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone Download PDF

Info

Publication number
AU2011261501B2
AU2011261501B2 AU2011261501A AU2011261501A AU2011261501B2 AU 2011261501 B2 AU2011261501 B2 AU 2011261501B2 AU 2011261501 A AU2011261501 A AU 2011261501A AU 2011261501 A AU2011261501 A AU 2011261501A AU 2011261501 B2 AU2011261501 B2 AU 2011261501B2
Authority
AU
Australia
Prior art keywords
resistant
leukemia
drug
certain embodiments
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011261501A
Other languages
English (en)
Other versions
AU2011261501A1 (en
Inventor
Kyle W.H. Chan
Frank Mercurio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioTheryX Inc
Original Assignee
BioTheryX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioTheryX Inc filed Critical BioTheryX Inc
Publication of AU2011261501A1 publication Critical patent/AU2011261501A1/en
Application granted granted Critical
Publication of AU2011261501B2 publication Critical patent/AU2011261501B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011261501A 2010-06-01 2011-06-01 Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone Ceased AU2011261501B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35043810P 2010-06-01 2010-06-01
US61/350,438 2010-06-01
PCT/US2011/038702 WO2011153199A1 (en) 2010-06-01 2011-06-01 Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone

Publications (2)

Publication Number Publication Date
AU2011261501A1 AU2011261501A1 (en) 2013-01-10
AU2011261501B2 true AU2011261501B2 (en) 2016-01-21

Family

ID=44534598

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011261501A Ceased AU2011261501B2 (en) 2010-06-01 2011-06-01 Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone

Country Status (8)

Country Link
US (2) US20130178503A1 (enExample)
EP (1) EP2585063A1 (enExample)
JP (1) JP6019015B2 (enExample)
CN (1) CN103153309A (enExample)
AU (1) AU2011261501B2 (enExample)
CA (1) CA2801003A1 (enExample)
MX (1) MX342465B (enExample)
WO (1) WO2011153199A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5844354B2 (ja) 2010-06-01 2016-01-13 ビオトヘルイク， インコーポレイテッド ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
WO2015195474A1 (en) 2014-06-18 2015-12-23 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
CN116077522B (zh) * 2023-03-09 2024-01-26 青岛市中心医院 一种用于治疗白血病的治疗制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005190A1 (en) * 1990-09-17 1992-04-02 The Children's Medical Center Corporation Deoxyhypusyl hydroxylase inhibitors
WO2010048712A1 (en) * 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883545A (en) 1968-08-31 1975-05-13 Hoechst Ag Certain 1-hydroxy-2-pyridones
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3972888A (en) 1972-03-25 1976-08-03 Hoechst Aktiengesellschaft Process for the preparation of 1-hydroxy-pyridones
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
JP3170176B2 (ja) * 1995-05-17 2001-05-28 大塚製薬株式会社 薬剤耐性獲得癌細胞の検出方法
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5846984A (en) * 1996-01-19 1998-12-08 The Trustees Of Columbia University In The City Of New York Use of ciclopirox or a pharmaceutically acceptable salt thereof for inhibiting neuronal cell damage or neuronal cell death
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DK0946169T3 (da) 1996-12-20 2003-04-22 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
EP1313473A2 (en) 2000-08-30 2003-05-28 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
AU2003201062A1 (en) * 2002-07-08 2004-01-23 Council Of Scientific And Industrial Research A pharmaceutical composition useful for treating chronic myeloid leukemia
WO2004007676A2 (en) * 2002-07-15 2004-01-22 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
AU2004298761A1 (en) * 2003-12-19 2005-06-30 Novartis Ag Combination of (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20080014192A1 (en) * 2006-05-23 2008-01-17 Poeta Maurizio D Methods For The Diagnosis And Treatment of Fungal Infections Caused By Microorganisms Producing Glucosylceramide
JP5766608B2 (ja) * 2008-10-02 2015-08-19 ヴェーイーベー ヴェーゼットウェーＶｉｂ Ｖｚｗ フィラデルフィア染色体陽性白血病を治療するためのＰｌＧＦの阻害

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005190A1 (en) * 1990-09-17 1992-04-02 The Children's Medical Center Corporation Deoxyhypusyl hydroxylase inhibitors
WO2010048712A1 (en) * 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BALABANOV, S., ET AL, "Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach". Blood, 2007, vol. 109, no. 4, pages 1701-1711 *
EBERHARD, Y., ET AL, "Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells". Blood, 2009, vol. 114, no. 14, pages 3064-3073 *
MOREL, F., ET AL, "Deletion of the 5' abl region in Philadelphia chromosome-positive chronic myeloid leukemia". Leukemia, 2003, vol. 17, pages 473-474 *
U.S. National Institutes of Health, ClinicalTrials.gov [retrieved 6 March 2014] Retrieved from the internet published 6 October 2009 *

Also Published As

Publication number Publication date
US20130178503A1 (en) 2013-07-11
US20150342942A1 (en) 2015-12-03
MX2012013878A (es) 2013-06-28
MX342465B (es) 2016-09-30
CA2801003A1 (en) 2011-12-08
CN103153309A (zh) 2013-06-12
AU2011261501A1 (en) 2013-01-10
EP2585063A1 (en) 2013-05-01
JP6019015B2 (ja) 2016-11-02
JP2013528620A (ja) 2013-07-11
WO2011153199A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
JP2025116875A (ja) 特定のｖｍａｔ２インヒビターを投与するための方法
JP2024107168A (ja) 特定のｖｍａｔ２インヒビターを投与するための方法
US8334307B2 (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
ES2928666T3 (es) Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas
AU2011261501B2 (en) Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
JP2022501390A (ja) 化合物及びその用途
AU2019282657B2 (en) Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease
JP2024516430A (ja) 肺がん治療のためのピリミジニルアミノベンゼン
AU2018247239A1 (en) Vitamin C and K for treating polycystic diseases
EP4106731A1 (en) Therapeutic agent nanoparticles and methods of preparation
CN115038447A (zh) 用于治疗癌症的组合疗法
US20170333392A1 (en) Vitamin c and vitamin k compound for treating pancreatic cancer
US20240197713A1 (en) Lfa-1 antagonists for treating inflammatory bowel diesease
JP7664429B2 (ja) Ｆｇｆｒ４選択的阻害剤の塩及びその製造方法と用途
JP2025507901A (ja) Ｐｉ３ｋ阻害剤とｐｄ－１阻害剤との併用療法
US20120015919A1 (en) Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists
WO2024094064A1 (en) Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired